SAN DIEGO , Sept. 18, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, will present a corporate update at the Jefferies Virtual Next Generation IBD Therapeutics Summit on Wednesday, September
- Evaluating etrasimod 2 mg in patients with the clinical diagnosis of moderately to severely active ulcerative colitis (UC) - Significant unmet need for new effective oral therapies in UC SAN DIEGO , Sept. 16, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
SAN DIEGO , Sept. 3, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that that members of its senior management team will participate in the upcoming investor conferences: Wells Fargo Virtual Healthcare Conference – Presenting on Wednesday, September 9 , at 1:20 PM
- Evaluating etrasimod 2 mg in patients with the clinical diagnosis of moderate-to-severe alopecia areata - There are currently no FDA-approved treatments for alopecia areata SAN DIEGO , Sept. 1, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the first
SAN DIEGO , Aug. 19, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on August 15, 2020 , the Compensation Committee of its Board of Directors granted to five new employees inducement stock options to purchase an aggregate of 15,275 shares of its common stock
SAN DIEGO , July 17, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on July 15, 2020 , the Compensation Committee of its Board of Directors granted to six new employees inducement stock options to purchase an aggregate of 35,850 shares of its common stock and
SAN DIEGO , June 18, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on June 15, 2020 , the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 80,250 shares of its common stock to 12 new employees and
SAN DIEGO , June 15, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the appointment of Dr. Katharine Knobil to the Company's Board of Directors. Dr. Knobil brings more than 20 years of leadership and expertise across a range of areas including global clinical
- Dr. Preston Klassen, Executive Vice President, Head of Research and Development, resigning - Dr. Chris Cabell appointed Executive Vice President, Head of Research and Development, and Chief Medical Officer SAN DIEGO , June 8, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
SAN DIEGO , June 1, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the completion of its previously announced underwritten public offering of 6,325,000 shares of its common stock at a price to the public of $50.00 per share, including 825,000 shares sold pursuant